

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INC.**

MONROE, LOUISIANA

FINANCIAL REPORT

AS OF AND FOR THE YEAR ENDED JUNE 30, 2019

BY

JIMMIE SELF, CPA

A PROFESSIONAL ACCOUNTING CORPORATION

2908 CAMERON STREET, SUITE – C

MONROE, LA 71201

Phone 318/323-4656 • Fax 318/388-0724

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INC.
Monroe, LA**

For the Year Ended June 30, 2019

TABLE OF CONTENTS

	<u>STATEMENTS</u>	<u>PAGE</u>
Independent Auditor's Report		1-3
<u>Financial Statements</u>		
Statement of Financial Position	A	5
Statement of Activities	B	6
Statement of Cash Flows	C	7
Statement of Functional Expenses	D	8
Notes to the Financial Statements		10-14
<u>Required Supplementary Information</u>		
Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance And Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>		16-18
<u>Additional Supplementary Information</u>		
	<u>SCHEDULE</u>	
Schedule of Financial Position	1	20
Schedule of Activities	2	21
Schedule of Cash Flows	3	22
Schedule of Functional Expenses	4	23
Schedule of Findings and Responses	5	24
Summary of Findings	6	25
Schedule of Board Members Compensation	7	26
Schedule of Compensation, Benefits and Other Payments to Agency Head or Chief Executive Officer	8	27
<u>Schedule of Budget to Actual</u>		
Genetic Disease Fund	9	29
United Way Fund	10	30

Jimmie L. Self, CPA
A Professional Accounting Corporation
2908 Cameron Street, Suite C
Monroe, LA 71201
Phone (318) 323-4656 • FAX (318) 388-0724

Independent Auditor's Report

To the Board of Directors
Northeast Louisiana Sickle Cell Anemia
Technical Resource Foundation, Inc.
Monroe, Louisiana

Report on the Financial Statements

I have audited the accompanying financial statements of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Inc., (a non-profit organization – the Foundation), which comprise the statement of financial position as of June 30, 2019, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

My responsibility is to express an opinion on these financial statements based on my audit. I conducted my audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that I plan and perform the audit to obtain reasonable assurance

Independent Auditor's Report

about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, I express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

Opinion

In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation as of June 30, 2019, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, I have also issued my report dated November 12, 2019, on my consideration of the Foundation's internal control over financial reporting and on my tests of its compliance with certain provisions of laws, regulations, contracts, grant agreements, and other matters. The purpose of that report is to describe the scope of my testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Foundation's internal control over financial reporting and compliance.

Additional supplementary Information

The additional supplementary information which also includes Schedule of Compensation, Benefits and Other Payments to Agency Head or Chief Executive Officer, and the Schedule of Budget to Actual, listed in the table of contents has not been

Independent Auditor's Report

subjected to the auditing procedures applied in the audit of the basic financial statements, and accordingly, I express no opinion on them.



Jimmie Self, CPA
Monroe, Louisiana
November 12, 2019

Financial Statements

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED

Statement of Financial Position

June 30, 2019

Assets

Current Assets:

Cash and Cash Equivalents	\$ 37,276
Receivables	4,900
Total Current Assets	42,176

Investments	21,986
-------------	--------

Physical Properties

Furniture and Equipment	27,584
Building	212,444
Vehicle	16,342
Accumulated Depreciation	(130,202)
Land	1,000
Total Physical Properties	127,168

Total Assets	191,330
--------------	---------

Liabilities and Net Assets

Current Liabilities:

Deferred Revenue	132,407
Total Current Liabilities	132,407

Long Term Liabilities

Line of Credit	3,878
Total Long Term Liabilities	3,878

Total Liabilities	136,285
-------------------	---------

Net Assets:

Without Donor Restrictions, Including \$127,168 Invested in Physical Properties	49,839
With Donor Restrictions	5,206
Total Net Assets	55,045

Total Liabilities and Net Assets	\$ 191,330
----------------------------------	------------

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED

Statement of Activities
For the Year Ended June 30, 2019

CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS

Contributions	\$ 33,730
Special Events	14,750
TOTAL REVENUE AND GAINS WITHOUT DONOR RESTRICTIONS	<u>48,480</u>
Net Assets Released from Restrictions	
Restrictions Satisfied by Payments	55,203
Total Reclassification Net Assets	<u>55,203</u>
TOTAL REVENUE, GAINS AND OTHER SUPPORT WITHOUT DONOR RESTRICTIONS	<u>103,683</u>
Expenses	
Program Expenses	56,807
General & Administrative Expenses	67,834
Total Expenses	<u>124,641</u>
INCREASE (DECREASE) IN NET ASSETS WITHOUT DONOR RESETRCTIONS	<u>(20,958)</u>
CHANGES IN NET ASSETS WITH DONOR RESRICTIONS	
Grants	55,203
Net Assets Released from Restrictions	
Restrictions Satisfied by Payments	<u>(55,203)</u>
INCREASE (DECREASE) IN NET ASSETS WITH DONOR RESETRCTIONS	<u>-</u>
Change in Net Assets	<u>(20,958)</u>
Net Assets as of Beginning of Year	<u>76,003</u>
Net Assets as of End of Year	<u><u>\$ 55,045</u></u>

See Accompanying Auditor's Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED

Statement of Cash Flows

For the Year Ended

June 30, 2019

Operating Activities

Change in Net Assets	\$ (20,958)
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities:	
Provision for Depreciation	6,250
Increase in Grants Receivable	(4,900)
Decrease in State of LA-Grant Refund	(5,102)
Decrease in Accrued Liabilities	(4)
Increase in Deferred Income	14,305
Prior Period Adjustment	-
Total Adjustments	<u>10,549</u>
Net Cash Provided by Operating Activities	<u>(10,409)</u>

Financing Activities

Principal Payments Line of Credit	<u>(334)</u>
Net Cash Provided by Financing Activities	<u>(334)</u>

Net Decrease in Cash	<u>(10,743)</u>
----------------------	-----------------

Cash and Cash Equivalents as of Beginning of Year	48,019
Cash and Cash Equivalents as of the End of Year	<u>\$ 37,276</u>

See Accompanying Auditor's Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Statement of Functional Expenses
 For the Year Ended
 June 30, 2019

	General and Administrative	Program	Total
Personnel Costs			
Salaries and Wages	\$ 28,425	\$ 20,980	\$ 49,405
Payroll Taxes and Other Fringe Benefits	\$ 3,072	\$ 2,726	5,798
Total Personnel Costs	<u>31,497</u>	<u>23,706</u>	<u>55,203</u>
Other Expenses			
Automobile Expense	5	5	10
Bank Service Charges	56	65	121
Banquet Expenses	8,199	-	8,199
Depreciation Expense	2,875	3,375	6,250
Insurance	2,650	3,111	5,761
Maintenance	682	800	1,482
Office Expense	3,467	4,069	7,536
Other Program Expense	-	356	356
Postage and Delivery	55	65	120
Printing and Publication	490	575	1,065
Professional/Contractual	9,957	-	9,957
Repairs & Maintenance	2,126	2,496	4,622
Specific Assistance to Individuals	-	11,405	11,405
Storage	304	356	660
Telephone	1,583	1,858	3,441
Travel	30	35	65
Utilities	3,858	4,530	8,388
Total Other Expenses	<u>36,337</u>	<u>33,101</u>	<u>69,438</u>
Total Functional Expenses	<u>\$ 67,834</u>	<u>\$ 56,807</u>	<u>\$ 124,641</u>

See Accompanying Auditor's Report and Notes to Financial Statements.

Notes to the Financial Statements

**Northeast Louisiana Sickle Cell Anemia Technical Resource
Foundation, Incorporated
Monroe, Louisiana**

**Notes to the Financial Statements
As of and for the Year Ended June 30, 2019**

NOTE A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

The Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated is a private non-profit organization domiciled in the State of Louisiana at Monroe, Louisiana. The Foundation is recognized as a tax-exempt (non-profit) organization under section 501 (c) (3) of the Internal Revenue Service Code. The Foundation is supported primarily through state and private grants, contributions and donations from members, and fundraisers. The objective of the Foundation is primarily to provide services to persons born with sickle cell anemia, a hereditary disorder. Such services include educational program, patient assistance programs, genetic counseling, research and social services. A Board of Directors consisting of fifteen (15) members governs the Foundation. The Board Members receive no compensation.

Basis of Accounting

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles.

Public Support and Revenue

In order to comply with restrictions that donors place on grants and other gifts as well as designations made by its governing board, the principles of reporting net assets are used. Revenue and public support consists mainly of state and private contracts, fundraising, and contributions. Contributions of cash and other assets are reported as net assets with donor restrictions if they are received with donor restrictions or restrictions designated by the governing board. Contributions are considered to be without restrictions unless restricted by the donor, and are reported as net assets without donor restrictions. All assets over which the Board of Directors has discretionary control have been included in the General Fund.

Depreciation

The Association follows the practice of capitalizing, at cost, all expenditures for fixed assets in excess of \$5,000. Depreciation is computed on a straight-line basis over the useful lives of the assets generally as follows:

Building and improvements	30 years
Furniture and equipment	7 years
Computers and accessories	5 years

The net fixed asset balance is reflected in the financial statements as a separate component in the net assets

Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated
Notes to Financial Statements (Continued)

Fair Value of Financial Instruments

The carrying amounts of cash, cash equivalents, investments, and notes payable are reported in the statement of financial position at approximate fair values because of the short maturity of those instruments.

Income Taxes

The organization is a nonprofit corporation, exempt under section 501 (c) (3) of the internal revenue code and did not conduct unrelated business activities. Accounting principles generally accepted in the United States of America require management to evaluate tax positions taken by the Organization and recognize a tax liability (or asset) if the Organization has taken an uncertain tax position that more likely than not would not be sustained upon examination by the IRS.

Management has analyzed the tax positions taken by the Organization, and has concluded that as of November 12, 2019, and there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Organization is subject to routine audits by Internal Revenue Service for the years ended June 30, 2019, 2018, and 2017; however, there are currently no audits for any tax period in progress.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates.

Cash and Cash Equivalents

The Foundation considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents for purposes of the statement of cash flows exclude permanently restricted cash and cash equivalents. Under state law, the agency may deposit funds in demand accounts, interest bearing accounts, money market accounts, or time deposits with state banks organized under Louisiana law and national banks having their principal offices in Louisiana. On June 30, 2019, Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated had cash and cash equivalents totaling \$37,276 as follows:

Without Donor Restrictions	\$	32,142
With Donor Restrictions		5,134
Total Cash	\$	<u>37,276</u>

Total Columns

Total columns are presented to facilitate financial analysis. Data in these columns do not present financial position, results of operations and changes in net assets in conformity with generally accepted accounting principles. Neither is such data comparable to a consolidation.

Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated
Notes to Financial Statements (Continued)

NOTE B. INVESTMENTS

The investments of the Foundation consisted of two (2) certificates of deposit at June 30, 2019 in the amounts of \$10,000 and \$11,986, totaling \$21,986. These certificates bear interest rates of 1.69% and 1.72%, respectively and both with automatic renewal terms and maturity every 182 days and 6 months. The entity has no known policy for custodial credit risk.

NOTE C. PHYSICAL PROPERTIES

Physical Properties consisted of the following at June 30, 2019:

	<u>Balance @</u> <u>7/1/18</u>	<u>Additions</u>	<u>Deletions</u>	<u>Balance @</u> <u>6/30/19</u>
Furniture and Equipment	\$ 27,584	\$ -	\$ -	\$ 27,584
Building	212,444	-	-	212,444
Vehicle	16,342			16,342
Less Accumulated Depreciaton	(123,952)	(6,250)		(130,202)
Sub Total	<u>132,418</u>	<u>(6,250)</u>	<u>-</u>	<u>126,168</u>
Land	1,000	-	-	1,000
Total	<u>\$ 133,418</u>	<u>\$ (6,250)</u>	<u>\$ -</u>	<u>\$ 127,168</u>

NOTE D. PENSION PLAN

All employees of the Foundation are members of the Social Security System. In addition to the employees' contribution of 7.65%, the agency contributes an amount of 7.65% to the Social Security System. The Foundation does not guarantee the benefits granted by the Social Security System.

NOTE E. DONATED SERVICES

The value of donated services is not reflected in the accompanying financial statements, since there is no objective basis available by which to measure the value of such services. However, for the purposes of this report the amounts are immaterial.

NOTE F. COMPENSATED ABSENCES

Compensated absences are absences for which employees will be paid, such as vacation, sick leave, and sabbatical leave. The Foundation has no policy for compensated absences. Therefore, those costs are not reflected in this report. However, for the purpose of this report the amounts are considered immaterial.

Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated
Notes to Financial Statements (Continued)

NOTE G. DEFERRED REVENUE

Deferred revenue consists of the following:

Temporarily Restricted	
United Way	\$ 132,407
Total	<u>\$ 132,407</u>

NOTE H. FUNCTIONAL ALLOCATION OF EXPENSES

The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

NOTE I. FUND DESCRIPTION

For internal accounting purposes, the Organization maintains the following separate funds:

General Fund

All assets over which the Board of Directors has discretionary control have been included in the General Fund.

United Way Fund

The United Way Fund is used to account for a grant from United Way of Northeast Louisiana.

Genetic Disease Fund

The Genetic Disease Fund is used to account for a state grant from the Louisiana Department of Health and Hospitals.

Walkathon Fund

The Walkathon Fund is used to account for proceeds from an annual fundraiser.

Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated
Notes to Financial Statements (Continued)

NOTE J. LIQUIDITY MANAGEMENT

As of June 30, 2019, the following financial assets could be made readily available within one year of the statement of financial position date to meet general expenditures:

Cash	\$ 37,276
Grants Receivable	<u>4,900</u>
Total	<u>\$ 42,176</u>

As part of its liquidity management, the Organization has a policy to structure its financial assets to be available as general expenditures, liabilities, and other obligations become due.

NOTE K. SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date that the financial statements were available to be issued, November 12, 2019, and determined that no events occurred that require disclosure. No subsequent events occurring after this date have been evaluated for inclusion in these financial statements.

Required Supplementary Information

Jimmie Self, CPA
A Professional Accounting Corporation
2908 Cameron St, Suite C
Monroe, LA 71201
Phone (318) 323-4656 • Fax (318) 388-0724

INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER
FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS
BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN
ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

To the Board of Directors
Northeast Louisiana Sickle Cell Anemia
Technical Resource Foundation, Inc.
Monroe, Louisiana

I have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Inc. (a non-profit organization), which comprise the statement of financial position as of June 30, 2019, and the related statements of activities, and cash flows for the year then ended, and the related notes to the financial statements, and have issued my report thereon dated November 12, 2019.

Internal Control over Financial Reporting

In planning and performing my audit of the financial statements, I considered Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Inc's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing my opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, I do not express an opinion on the effectiveness of the Foundation's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. *A material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. *A significant deficiency* is a deficiency, or a combination of deficiencies, in internal control

that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

My consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. Given these limitations, during my audit I did not identify any deficiencies in internal control that I consider to be material weaknesses. I did identify certain deficiencies in internal control, described in the accompanying schedule of findings and responses that I consider to be a significant deficiency in internal control over financial reporting, item # 2019-01.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Foundation's financial statements are free from material misstatement, I performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of my audit, and accordingly, I do not express such an opinion. The results of my tests disclosed one instance of noncompliance or other matters that are required to be reported under *Government Auditing Standards* and which are described in the accompanying schedule of findings and responses as item # 2019-01. The Foundation's response to the findings identified in my audit is described in the accompanying schedule of findings and responses.

Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Inc.'s Response to Findings

The Foundation's response to the findings identified in my audit is described in the accompanying schedule of findings and responses. The Foundation's response was not subjected to the auditing procedures applied in the audit of the financial statements and, accordingly, I express no opinion on it.

Purpose of this Report

The purpose of this report is solely to describe the scope of my testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Foundation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the organization's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

This report is intended solely for the information and use of management of the Foundation, others within the Foundation, and the Louisiana Legislative Auditor and

federal awarding agencies and pass-through entities and is not intended to be and should not be used by anyone other than these specified parties. Under Louisiana Revised Statute 24:513, this report is distributed by the Legislative Auditor as a public document.

A handwritten signature in cursive script that reads "Jimmie Self, CPA".

Jimmie Self, CPA
Monroe, Louisiana
November 12, 2019

Additional Supplementary Information

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Financial Position
June 30, 2019

	Temporarily Restricted				Total All Funds
	General Fund	United Way	Genetic Disease Fund	Walkathon Fund	
Assets					
Current Assets:					
Cash and Cash Equivalents	\$ 16,928	\$ 5,135	\$ 15,213	\$ -	\$ 37,276
Receivables	-	-	4,900	-	4,900
Due From Other Funds	20,113	127,272	-	5,206	152,591
Total Current Assets	<u>37,041</u>	<u>132,407</u>	<u>20,113</u>	<u>5,206</u>	<u>194,767</u>
Investments	21,986	-	-	-	21,986
Physical Properties					
Furniture and Equipment	26,939	-	645	-	27,584
Building	212,444	-	-	-	212,444
Vehicle	16,342	-	-	-	16,342
Accumulated Depreciation	(129,557)	-	(645)	-	(130,202)
Land	1,000	-	-	-	1,000
Total Physical Properties	<u>127,168</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>127,168</u>
Total Assets	<u>186,195</u>	<u>132,407</u>	<u>20,113</u>	<u>5,206</u>	<u>343,921</u>
Liabilities and Net Assets					
Current Liabilities:					
Accrued Liabilities	-	-	-	-	-
Due to Other Funds	132,478	-	20,113	-	152,591
Deferred Revenue	-	132,407	-	-	132,407
State of LA - Grant Refund	-	-	-	-	-
Total Current Liabilities	<u>132,478</u>	<u>132,407</u>	<u>20,113</u>	<u>-</u>	<u>284,998</u>
Long Term Liabilities					
Line of Credit	3,878	-	-	-	3,878
Total Long Term Liabilities	<u>3,878</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>3,878</u>
Total Liabilities	<u>136,356</u>	<u>132,407</u>	<u>20,113</u>	<u>-</u>	<u>288,876</u>
Net Assets:					
Without Donor Restrictions, Including \$127,168 Invested in Physical Properties	49,839	-	-	-	49,839
With Donor Restrictions	-	-	-	5,206	5,206
Total Net Assets	<u>49,839</u>	<u>-</u>	<u>-</u>	<u>5,206</u>	<u>55,045</u>
Total Liabilities and Net Assets	<u>\$ 186,195</u>	<u>\$ 132,407</u>	<u>\$ 20,113</u>	<u>\$ 5,206</u>	<u>\$343,921</u>

See Accompanying Auditor's Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Activities
For the Year Ended
June 30, 2019

	Without Donor Restrictions	With Donor Restrictions			Total All Funds
	General Fund	United Way	Genetic Disease Fund	Walkathon Fund	
CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS					
Contributions	\$ 33,730	\$ -	\$ -	\$ -	\$ 33,730
Banquet Proceeds	-	-	-	-	-
Investment Income	-	-	-	-	-
Special Events	14,750	-	-	-	14,750
TOTAL REVENUE AND GAINS WITHOUT DONOR RESTRICTIONS	48,480	-	-	-	48,480
Net Assets Released from Restrictions					
Restrictions Satisfied by Payments	55,203	-	-	-	55,203
Total Net Assets Released from Restrictions	55,203	-	-	-	55,203
TOTAL REVENUE, GAINS AND OTHER SUPPORT WITHOUT DONOR RESTRICTIONS	103,683	-	-	-	103,683
Expenses					
Program Expenses	56,807	-	-	-	56,807
General & Administrative Expenses	67,834	-	-	-	67,834
Total Expenses	124,641	-	-	-	124,641
INCREASE (DECREASE) IN NET ASSETS WITHOUT DONOR RESETRICIONS	(20,958)	-	-	-	(20,958)
CHANGES IN NET ASSETS WITH DONOR RESRICTIONS					
Contribution	-	-	-	-	-
Grants	-	14,203	41,000	-	55,203
Net Assets Released from Restrictions					
Restrictions Satisfied by Payments	-	(14,203)	(41,000)	-	(55,203)
INCREASE (DECREASE) IN NET ASSETS WITH DONOR RESETRICIONS	-	-	-	-	-
Other Financing Sources (Uses)					
Transfer In (Out)	-	-	-	-	-
Total Other Financing Sources and Uses	-	-	-	-	-
Change in Net Assets	(20,958)	-	-	-	(20,958)
Net Assets as of Beginning of Year	70,797	-	-	5,206	76,003
Other Changes in Net Assets					
Prior Period Adjustment	-	-	-	-	-
Total Other Changes in Net Assets	-	-	-	-	-
Net Assets as of End of Year	\$ 49,839	\$ -	\$ -	\$ 5,206	\$ 55,045

See Accompanying Auditor's Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Cash Flows
For the Year Ended
June 30, 2019

	Unrestricted	Temporarily Restricted			Total All Funds
	General Fund	United Way	Genetic Disease Fund	Walkathon Fund	
Operating Activities					
Change in Net Assets	\$ (20,958)	\$ -	\$ -	\$ -	\$ (20,958)
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities:					
Provision for Depreciation	6,250	-	-	-	6,250
Decrease (Increase) in Due from Other Funds	11,600	(13,497)	-	-	(1,897)
Increase (Decrease) in Grants Receivable	-	-	(4,900)	-	(4,900)
Increase (Decrease) in Accrued Liabilities	(4)	-	-	-	(4)
Increase (Decrease) in Due to Other Funds	13,497	-	(11,600)	-	1,897
Increase (Decrease) in State of LA -Grant Refund	-	-	(5,102)	-	(5,102)
Increase (Decrease) in Deferred Income	-	14,305	-	-	14,305
Prior Period Adjustment	-	-	-	-	-
Total Adjustments	<u>31,343</u>	<u>808</u>	<u>(21,602)</u>	<u>-</u>	<u>10,549</u>
Net Cash Provided by Operating Activities	<u>10,385</u>	<u>808</u>	<u>(21,602)</u>	<u>-</u>	<u>(10,409)</u>
Investing Activities					
Cash Invested in Certificate of Deposit	-	-	-	-	-
Net Cash Provided by Investing Activities	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Financing Activities					
Principal Payments on Line Credit	(334)	-	-	-	(334)
Net Cash Provided by Financing Activities	<u>(334)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(334)</u>
Net Increase (Decrease) in Cash	<u>10,051</u>	<u>808</u>	<u>(21,602)</u>	<u>-</u>	<u>(10,743)</u>
Cash and Cash Equivalents as of Beginning of Year	6,877	4,327	36,815	-	48,019
Cash and Cash Equivalents as of the End of Year	<u>\$ 16,928</u>	<u>\$ 5,135</u>	<u>\$15,213</u>	<u>\$ -</u>	<u>\$ 37,276</u>

See Accompanying Auditor's Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Functional Expenses
For the Year Ended
June 30, 2019

	Temporarily Restricted Net Assets Released From Restrictions				Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
Program Expenses					
Personnel Costs					
Salaries and Wages	\$ -	\$ 5,661	\$ 15,319	\$ -	\$ 20,980
Payroll Taxes and Other Fringe Benefits	-	1,772	954	-	2,726
Total Personnel Costs	-	7,433	16,273	-	23,706
Other Expenses					
Automobile Expense	5	-	-	-	5
Bank Charges	65	-	-	-	65
Depreciation Expense	3,375	-	-	-	3,375
Insurance	3,111	-	-	-	3,111
Maintenance	800	-	-	-	800
Office Expense	4,069	-	-	-	4,069
Postage and Delivery	65	-	-	-	65
Printing and Publication	575	-	-	-	575
Program Expenses	356	-	-	-	356
Repairs & Maintenance	2,496	-	-	-	2,496
Specific Assistance to Individuals	11,405	-	-	-	11,405
Storage	356	-	-	-	356
Telephone	1,858	-	-	-	1,858
Travel	35	-	-	-	35
Utilities	4,530	-	-	-	4,530
Total Other Expenses	33,101	-	-	-	33,101
Total Program Expenses	\$ 33,101	\$ 7,433	\$ 16,273	\$ -	\$ 56,807
General & Administrative Expenses					
Personnel Costs					
Salaries and Wages	\$ -	\$ 6,081	\$ 22,344	\$ -	\$ 28,425
Payroll Taxes and Other Fringe Benefits	-	689	2,383	-	3,072
Total Personnel Costs	-	6,770	24,727	-	31,497
Other Expenses					
Automobile Expense	5	-	-	-	5
Bank Charges	56	-	-	-	56
Banquet Expenses	8,199	-	-	-	8,199
Conferences, Conventions, & Meetings	-	-	-	-	-
Depreciation Expense	2,875	-	-	-	2,875
Dues and Subscription	-	-	-	-	-
Interest Expense	-	-	-	-	-
Insurance	2,650	-	-	-	2,650
Licenses and Permits	-	-	-	-	-
Maintenance	682	-	-	-	682
Office Expense	3,467	-	-	-	3,467
Other Program Expense	-	-	-	-	-
Postage and Delivery	55	-	-	-	55
Printing and Publication	490	-	-	-	490
Professional Fees	9,957	-	-	-	9,957
Repairs & Maintenance	2,126	-	-	-	2,126
Storage	304	-	-	-	304
Supplies	-	-	-	-	-
Telephone	1,583	-	-	-	1,583
Travel	30	-	-	-	30
Utilities	3,858	-	-	-	3,858
Worker's Compensation	-	-	-	-	-
Total Other Expenses	36,337	-	-	-	36,337
Total General & Administrative Expenses	36,337	6,770	24,727	-	67,834
Total Functional Expenses	\$ 69,438	\$ 14,203	\$ 41,000	\$ -	\$ 124,641

See Accompanying Auditor's Report and Notes to Financial Statements.

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INC.
MONROE, LA
SCHEDULE OF FINDINGS AND RESPONSES**

For the Year Ended June 30, 2019

FINDING: 2019-1

CONDITION: Inadequate segregation of duties

CRITERIA: Duties should be distributed among employees.

CAUSE OF CONDITION: The staff consists of only one clerk.

EFFECT OF CONDITION: Internal control is weakened by the limited staff.

RECOMMENDATION: Hire more employees and redistribute duties.

CLIENT RESPONSE: Management states this cannot be remedied due to lack of funds.

FINANCIAL IMPACT OF FINDING: Finding without cause- resolution of finding is under the control of the agency and would be cost effective.

SCHEDULE OF PRIOR YEAR FINDINGS AND RESPONSES

For the Year Ended June 30, 2018

FINDING: 2018-1

CONDITION: No segregation of duties

CRITERIA: Duties should be distributed among employees.

CAUSE OF CONDITION: The staff consists of only one clerk.

EFFECT OF CONDITION: Internal control is weakened by the limited staff.

RECOMMENDATION: Hire more employees and redistribute duties.

CLIENT RESPONSE: Management states this cannot be remedied due to lack of funds.

FINANCIAL IMPACT OF FINDING: Finding without cause- resolution of finding is under the control of the agency.

STATUS: CLEARED

Jimmie Self, CPA
A Professional Accounting Corporation
2908 Cameron Street, Suite C
Monroe, Louisiana 71201
Phone (318) 323-4656 Fax (318) 388-0724

SCHEDULE 6

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION. INC.
MONROE, LA**

SUMMARY OF FINDINGS

For The Year Ended June 30, 2019

I have audited the financial statements of the Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Inc, and have issued my report dated November 12, 2019. My audit of the financial statements as of June 30, 2019, resulted in an unqualified opinion.

Section I - Summary of Auditor's Reports

Report on Internal Control and Compliance Material to the Financial Statements

Internal Control

Material Weaknesses yes x no Internal Control Deficiencies x yes no

Compliance

Compliance material to Financial Statements yes x no

Jimmie L. Self, CPA
A Professional Accounting Corporation
2908 Cameron Street, Suite C
Monroe, LA 71201
Phone (318) 323-4656 • FAX (318) 388-0724

Schedule of Board Members Compensation

SCHEDULE 7

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA TECHNICAL RESOURCE
FOUNDATION, INC.
06/30/2019**

Dr. Pamela Saulsberry	117 Vegas Drive, Monroe, LA 72102	President	318-342-1445
Mrs. Bobbie Butler	4705 Lincoln Park Dr., Monroe, LA 71202	Treasurer	318-387-9565
Mrs. Mayme Corbin	2782 Winnsboro Rd., Monroe, LA 71202	Secretary	318- 323-1836
Mr. George Britton	P. O. Box 1347, Monroe, LA 71210-1347		318-323-8277
Mrs. Gina Jones White	1409 Parkview Drive, Monroe, LA 71202		318-803-7175
Sandra Daniel	819 Stubb Vinson, Monroe, LA 712032		318-547-9243
Terry Matthews	1003 Commerce Ave, Bastrop, LA 71220		318-547-6931
Ms. Tazinski Lee	1206 Walton Lane, Monroe, LA 71203		318-503-1979
Helen Givens	311 Evers, Monroe, LA 71202		318-557-9985
Mrs. Juantia Woods	City of Monroe Council District 3 P.O. Box 123 Monroe, Louisiana		318-329-2261
Dr. Rhonda Pruitt	7412v Hwy. 80 Ruston, LA 71270		318-247-1222
Mr. Lance Griffith	3309 Bearivoir Place Monroe, LA 71202		318-348-4076

Note: Board Members do not receive any form of financial compensation.

SCHEDULE 8

Northeast Louisiana Sickle Cell Anemia
 Technical Resource Foundation, Inc.
 Monroe, Louisiana
06/30/2019

Schedule of Compensation,
 Benefits and Other Payments to Agency Head
 or Chief Executive Officer

Agency Head Name: Donna Thaxton, Executive Director, who received \$27,840, with no other benefits.

Purpose	Amount
Salary	
Benefits-insurance	0
Benefits-retirement	0
Benefits-<list any other here>	0
Car allowance	0
Vehicle provided by government	0
Per diem	0
Reimbursements	0
Travel	0
Registration fees	0
Conference travel	0
Continuing professional education fees	0
Housing	0
Unvouchered expenses*	0
Special meals	0

Donna Thaxton, Executive Director, received \$27,840.

Betty Jackson, office manager received \$9,120 and Chery Minor received \$15,096.
 No other benefits are received except social security for the fiscal year ended 06-30-2019.

All board members received no compensation, and **no** other benefits for the fiscal year ended 06/30/2019.

SCHEDULE OF BUDGET TO ACTUAL

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Genetic Disease Fund
Budget to Actual
June 30, 2019**

	<u>Budgeted</u>	<u>Actual</u>	<u>Variance</u>
Revenue			
Grants	41,200	41,000	200
Total Revenue	<u>41,200</u>	<u>41,000</u>	<u>200</u>
Personnel Costs			
Salaries and Wages	39,925	37,663	2,262
Payroll Taxes and Other Fringe Benefits	1,275	3,337	(2,062)
Total Personnel Costs	<u>41,200</u>	<u>41,000</u>	<u>200</u>
Other Expenses			
Personnel Travel	-	-	-
Operating Services	-	-	-
Operating Supplies	-	-	-
Total Other Expenses	<u>-</u>	<u>-</u>	<u>-</u>
Total Expenses	<u>41,200</u>	<u>41,000</u>	<u>200</u>
Change in Net Assets	<u>-</u>	<u>-</u>	<u>-</u>

See Accompanying Auditor's Report and Notes to Financial Statements.

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**

**United Way Fund
Budget to Actual
June 30, 2019**

	<u>Budgeted</u>	<u>Actual</u>	<u>Variance</u>
Revenue			
Grants	32,514	14,203	18,311
Contributions	-	-	-
Total Revenue	<u>32,514</u>	<u>14,203</u>	<u>18,311</u>
 Personnel Costs			
Salaries and Wages	29,937	11,742	18,195
Payroll Taxes and Other Fringe Benefits	2,577	2,461	116
Total Personnel Costs	<u>32,514</u>	<u>14,203</u>	<u>18,311</u>
 Other Expenses	<u>-</u>	<u>-</u>	<u>-</u>
 Total Expenses	<u>32,514</u>	<u>14,203</u>	<u>18,311</u>
 Change in Net Assets	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>

See Accompanying Auditor's Report and Notes to Financial Statements.